Provided by Tiger Fintech (Singapore) Pte. Ltd.

Krystal Biotech Inc.

148.18
-2.2300-1.48%
Volume:101.06K
Turnover:15.14M
Market Cap:4.28B
PE:35.66
High:152.05
Open:150.64
Low:147.79
Close:150.41
Loading ...

Krish S. Krishnan, President and CEO of Krystal Biotech, Reports Disposal of Common Shares

Reuters
·
12 Jul

Krystal Biotech Is Maintained at Neutral by Citigroup

Dow Jones
·
11 Jul

TD Cowen Sticks to Their Buy Rating for Krystal Biotech (KRYS)

TIPRANKS
·
10 Jul

Krystal Biotech price target raised to $176 from $155 at Citi

TIPRANKS
·
10 Jul

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

THOMSON REUTERS
·
09 Jul

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

GlobeNewswire
·
09 Jul

Krystal Biotech (NASDAQ:KRYS) shareholder returns have been strong, earning 249% in 5 years

Simply Wall St.
·
05 Jul

Krystal Biotech Initiated at Buy by Clear Street

Dow Jones
·
01 Jul

Krystal Biotech initiated with a Buy at Clear Street

TIPRANKS
·
01 Jul

Krystal Biotech Price Target Maintained With a $240.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Jun

BRIEF-Krystal Biotech Announces First Patient Dosed In Phase 3 Clinical Trial Of Kb803 For The Treatment And Prevention Of Corneal Abrasions

Reuters
·
24 Jun

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa

THOMSON REUTERS
·
24 Jun

Krystal Biotech Inc. Conducted Annual Meeting of Stockholders

Reuters
·
20 May

Krystal Biotech Is Maintained at Neutral by Citigroup

Dow Jones
·
17 May

Krystal Biotech price target lowered to $155 from $215 at Citi

TIPRANKS
·
16 May

Krystal Biotech (KRYS) Receives a Buy from Evercore ISI

TIPRANKS
·
13 May

Evercore ISI Keeps Their Buy Rating on Krystal Biotech (KRYS)

TIPRANKS
·
08 May

Krystal Biotech Is Maintained at Buy by Chardan Capital

Dow Jones
·
07 May

Krystal Biotech Price Target Maintained With a $240.00/Share by HC Wainwright & Co.

Dow Jones
·
07 May

Krystal Biotech Shares Slip After 1Q Miss

Dow Jones
·
07 May